Clinical application of volatile organic compound analysis for detecting infectious diseases

Clinical Microbiology Reviews

Volumn 26, Issue 3, 2013, Pages 462-475

  Sethi, Shneh ^a   Nanda, Ranjan ^b   Chakraborty, Trinad ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTANONE; ACETIC ACID ETHYL ESTER; BIOLOGICAL MARKER; HYDROGEN CYANIDE; REACTIVE OXYGEN METABOLITE; UREA C 13; VOLATILE ORGANIC COMPOUND;

ARTICLE; ASPERGILLOSIS; BREATH ANALYSIS; CHEMICAL ANALYSIS; CYSTIC FIBROSIS; GASTROINTESTINAL INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION; ION MOBILITY SPECTROMETRY; MASS FRAGMENTOGRAPHY; METABOLITE; NONHUMAN; OXIDATIVE STRESS; POINT OF CARE TESTING; PSEUDOMONAS INFECTION; SENSITIVITY AND SPECIFICITY; SENSOR; SOLID PHASE MICROEXTRACTION; TIME OF FLIGHT MASS SPECTROMETRY; TUBERCULOSIS; URINARY TRACT INFECTION;

BREATH TESTS; COMMUNICABLE DISEASES; HUMANS; VOLATILE ORGANIC COMPOUNDS;

EID: 84879760975     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00020-13     Document Type: Article

References (135)

1. Risby TH. 2002. Volatile organic compounds as markers in normal and diseased states, p 113. In Proceedings of the NATO Advanced Study Institute on Disease Markers in Exhaled Breath, 22 June to 1 July 2001, Limin Hersonissou, Crete, Greece.
2. Shirasu M, Touhara K. 2011. The scent of disease: volatile organic compounds of the human body related to disease and disorders. J. Biochem. 150:257-266.
3. Dummer J, Storer Swanney M, McEwan M, Scott-Thomsad A, Bhandari S, Chambers S, Dweik R, Epton M. 2011. Analysis of biogenic volatile organic compounds in health and disease. Trends Anal. Chem. 30:960-967.
4. Cicolella A. 2008. Volatile organic compounds (VOC): definition, classification and properties. Rev. Mal. Respir. 25:155-163.
5. Phillips M. 1992. Breath tests in medicine. Sci. Am. 7:74-79.
6. Miekisch W, Schubert JK, Gabriele FE, Noelge-Schomburg GFE. 2004. Diagnostic potential of breath analysis-focus on volatile organic compounds. Clin. Chim. Acta 347:25-39.
7. Amann A., Smith D (ed). 2005. Breath analysis for clinical diagnosis and therapeutic monitoring. World Scientific, Singapore, Republic of Singapore.
8. Cao W, Duan Y. 2006. Breath analysis: potential for clinical diagnosis and exposure assessment. Clin. Chem. 52:800-811.
9. Smith D, Spanel P. 2007. The challenge of breath analysis for clinical diagnosis and therapeutic monitoring. Analyst 132:390-396.
10. Boots AW, van Berkel JJBN, Dallinga JW, Smolinska A, Wouters MFM, van Schooten FJ. 2012. The versatile use of exhaled volatile organic compounds in health and disease. J. Breath Res. 6:027108. doi: 10.1088/1752-7155/6/2/027108.
11. Buszewski B, Kesy M, Ligor T, Amann T. 2007. Human exhaled air analytics: biomarker of diseases. Biomed. Chromatogr. 21:553-566.
12. Guernion N, Ratcliffe M, Spencer-Phillips PT, Howe RA. 2001. Identifying bacteria in human urine: current practice and the potential for rapid, near-patient diagnosis by sensing volatile organic compounds. Clin. Chem. Lab. Med. 39:893-906.
13. Garner CE, Smith S, Costello B, White P, Spencer R, Prober CSJ, Ratcliffe M. 2007. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 1675-1688.
14. Phillips M, Cataneo RN, Cheema T, Greenberg J. 2004. Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin. Chim. Acta 344:189-194.
15. Galassetti PR, Novak B, Nemet D, Rose-Gottron C, Cooper DM, Meinardi S, Neocomb R, Zaldivar F, Blake DR. 2005. Breath ethanol and acetone as indicators of serum glucose levels: An initial report. Diabetes Technol. Ther. 7:115-123.
16. Novak BJ, Blake DR, Meinardi S, Rowland FS, Pontello A, Cooper DM, Galassetti PR. 2007. Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 104:15613-15618.
17. Probert CSJ, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. 2009. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J. Gastrointestin. Liver Dis. 18:337-343.
18. Robroeks CM, van Berkel JJBN, Dallinga JW, Jobsis Q, Zimmermann LJI, Hendriks HJE, Wouters MFM, van der Grinten CPM, van de Kant KDG, van Schooten FJ, Dompeling E. 2010. Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. Pediatr. Res. 68:75-80.
19. Phillips M, Cataneo RN, Ditkoff BN, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C. 2003. Volatile biomarkers of breast cancer in the breath. Breast J. 9:184-191.
20. Mazzone PJ. 2008. Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J. Thorac. Oncol. 3:774-780.
21. Horvath I, Lazar Z, Gyulai N, Kollai M, Losonczy G. 2009. Exhaled biomarkers in lung cancer. Eur. Respir. J. 34:261-275.
22. Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, Haick H. 2012. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem. Rev. 112:5949-5966.
23. Phillips M, Cataneo RN, Condos R, Ring Erikson GA, Greenberg J, La Bombardi V, Munawar MI, Tietje O. 2007. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 87:44-52.
24. Chambers ST, Scott-Thomas A, Epton M. 2012. Developments in novel breath tests for bacterial and fungal pulmonary infection. Curr. Opin. Pulm. Med. 18:228-232.
25. Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. 2008. GC-MS analysis of breath odor compounds in liver patients. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 875:344-348.
26. Vereb H, Dietrich AM, Alfeeli B, Agah M. 2011. The possibilities will take your breath away: breath analysis for assessing environmental exposure. Environ. Sci. Technol. 45:8167-8175.
27. Cao W, Duan Y. 2007. Current status of methods and techniques for breath analysis. Crit. Rev. Anat. Chem. 37:3-13.
28. Herbig J, Müller M, Schallhart S, Titzmann T, Graus M, Hansel A. 2009. On-line breath analysis with PTR-TOF. J. Breath Res. 3:027004. doi:10.10888/1752-7155/3/2/027004.
29. Zhang Z, Li JA. 2010. The review of advances and new developments in the analysis of biological volatile organic compounds. Microchem. J. 95:127-139.
30. Wojtas J, Bielecki Z, Stacewicz T, Mikolajczyk J, Nowakowski M. 2012. Ultrasensitive laser spectroscopy for breath analysis. Opto-Electron. Rev. 20:26-39.
31. Pavlou AK, Turner APF. 2000. Sniffing out the truth: clinical diagnosis using the electronic nose. Clin. Lab. Med. 38:99-112.
32. Turner APF, Magan N. 2004. Electronic noses and disease diagnostics. Nat. Rev. Microbiol. 2:161-166.
33. Shnayderman M, Mansfield B, Yip P, Clark HA, Krebs MD, Cohen SJ, Zeskind JE, Ryan ET, Dorkin HL, Callahan MV, Stair TO, Gelfand JA, Gill CJ, Hitt B, Davis CE. 2005. Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition. Anal. Chem. 77:5930-5937.
34. Schulz S, Dickschat JS. 2007. Bacterial volatiles: the smell of small organisms. Nat. Prod. Rep. 24:814-842.
35. Jünger M, Vautz W, Kuhns M, Hofmann L, Ulbricht S, Baumbach JI, Quintel M, Perl T. 2012. Ion mobility spectrometry for microbial volatile organic compounds: a new identification tool for human pathogenic bacteria. Appl. Microbiol. Biotechnol. 93:2603-2614.
36. Steeghs MML, Cristescu SM, Harren FJM. 2007. The suitability of Tedlar bags for breath sampling in medical diagnostic research. Physiol. Meas. 28:73-84.
37. Pleil JD, Lindstrom AB. 1995. Measurement of volatile organic compounds in exhaled breath as collected in evacuated electropolished canisters. J. Chromatogr. B Biomed. Appl. 665:271-279.
38. Phillips M. 1997. Method for the collection and assay of volatile organic compounds in breath. Anal. Biochem. 247:272-278.
39. Grote C, Pawliszyn J. 1997. Solid-phase microextraction for the analysis of human breath. Anal. Chem. 69:587-596.
40. Lord H, Yu Y, Segal A, Pawliszyn J. 2002. Breath analysis and monitoring by membrane extraction with sorbent interface. Anal. Chem. 74: 5650-5657.
41. Effros RM. 2010. Exhaled breath condensate: delusion or dilution? Chest 138:471-472.
42. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H, ATS/ERS Task Force on Exhaled Breath Condensate. 2005. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 26:523-548.
43. Kneepkens CME, Lepage G, Roy CC. 1994. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic. Biol. Med. 17:127-160.
44. Baumbach JI. 2008. Ion mobility spectrometry coupled with multicapillary columns for metabolic profiling of human breath. J. Breath Res. 3:034001. doi:10.1088/1752-7155/3/3/034001.
45. Amann A, Poupart G, Telser S, Ledochowski M, Schmidt A, Mechtcheriakov S. 2004. Applications of breath gas analysis in medicine. Int. J. Mass Spectrom. 239(2-3):227-233.
46. Spanel P, Smith D. 2011. Progress in SIFT-MS: breath analysis and other applications. Mass Spectrom. Rev. 30:236-267.
47. Maniewski R, Liebert A, Kacprzak M, Zbiec A. 2004. Selected application of near-infrared optical methods in medical diagnosis. Opto- Electron. Rev. 12:255-262.
48. Rock F, Barsan N, Weimar U. 2008. Electronic nose: current status and future trends. Chem. Rev. 108:705-725.
49. Wilson AD, Baietto M. 2011. Advances in electronic-nose technologies developed for biomedical applications. Sensors 11:1105-1176.
50. Hines EL, Lloblet E, Gardner JW. 1996. Electron noses: review of signal processing techniques: IEE Proc. Circuits Syst. 146:297-310.
51. Tisch U, Haick H. 2010. Nanomaterials for cross reactive sensor arrays. MRS Bull. 35:797-803.
52. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Haick H. 2009. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 4:669-673.
53. Pearce TC. 1997. Computational parallels between the biological olfactory pathway and its analogue in electronic nose part II: sensor based machine olfaction. Biosystems 41:69-90.
54. Staples EJ. 1999. A new electronic nose. Sensors 16:33-40.
55. Staples EJ. 2000. The z Nose, a new electronic nose using acoustic technology. J. Acoust. Soc. Am. 108:2495.
56. Moser E, McCulloch M. 2010. Canine scent detection of human cancers. A review of methods and accuracy. J. Vet. Behav. 5:145-152.
57. Weetjens BJ, Mgode GF, Machangu RS, Kazwala R, Mfinanga G, Lwilla F, Cox C, Jubitana A, Kanyagha H, Mtandu R, Kahwa A, Mwessongo J, Makingi G, Mfaume S, Van Steenberge J, Beyene NW, Billet M, Verhagen R. 2009. African pouched rats for the identification of pulmonary tuberculosis in sputum. Int. J. Tuberc. Lung Dis. 13:737-743.
58. Stotzky G, Schneck S. 1976. Volatile organic compounds and microorganisms. Crit. Rev. Microbiol. 4:333-382.
59. Lechner M, Fille M, Hausdorfer J, Dierich MP, Rieder J. 2005. Diagnosis of bacteria in vitro by mass spectrometric fingerprinting: a pilot study. Curr. Microbiol. 51:267-269.
60. Bruins M, Bos A, Petit PLC, Eadie K, Rog A, Bos R, van Ramshorst GH, van Belkum A. 2009. Device-independent, real-time identification of bacterial pathogens with a metal oxide-based olfactory sensor. Eur. J. Clin. Microbiol. Infect. Dis. 28:775-780.
61. Lawn SD, Zumla A. 2011. Tuberculosis. Lancet 378:57-72.
62. Wallis RS, Paiu M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. 2010. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937.
63. Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimmerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S. 2012. Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J. Infect. Dis. 205(Suppl 2): S159-S168. doi:10.1093/infdis/jis194.
64. McNerney R, Daley P. 2011. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat. Rev. Microbiol. 9:204-213.
65. Omelianski VL. 1923. Aroma-producing microorganisms. J. Bacteriol. 8:393-419.
66. Pavlou AK, Magan N, Jones J, Brown J, Klaster P, Turner A. 2004. Detection of Mycobacterium tuberculosis (TB) in vitro and in situ using electronic nose detection in combination with a neural network system. Biosens. Bioelectron. 20:538-544.
67. Fend R, Kolk AHJ, Bessant C, Buijtels P, Klaster PR, Woodman AC. 2006. Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J. Clin. Microbiol. 44:2039-2045.
68. Kolk A, Hoelscher M, Maboko L, Jung J, Kuijper S, Cauchiu M, Bessant C, van Beers S, Dutta R, Gibson T, Reither K. 2010. Electron nose technology using sputum samples in diagnosis of patients with tuberculosis. J. Clin. Microbiol. 48:4235-4238.
69. Syhre M, Chambers ST. 2008. The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 88:317-323.
70. Syhre M, Manning L, Phuanukoonnon S, Harino P, Chambers ST. 2009. The scent of Mycobacterium tuberculosis-part II breath. Tuberculosis (Edinb.) 89:263-266.
71. Phillips M, Cantaneo RN, Condos R, Gerald A, Erickson R, Greenberg J, La Bombardi V, Munawar MI, Tietje O. 2007. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb.) 87:44-52.
72. Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MPR, Schmitt P, Wai J. 2010. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb.) 90:145-151.
73. Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, Pandya M, Natividad MPR, Patel U, Ramraje NN, Schmitt P, Udwadia ZF. 2012. Point-of-care breath test for biomarkers of active tuberculosis. Tuberculosis (Edinb.) 92:314-332.
74. Kolk AHJ, Van Berkel JJBN, Claassens MM, Walters E, Kuijper S, Dallinga JW, van Schooten FJ. 2012. Breath analysis as a potential diagnostic tool for tuberculosis. Int. J. Tuberc. Lung Dis. 16:777-782.
75. Risby TH, Sehnert SS. 1999. Clinical application of breath biomarkers of oxidative stress status. Free Radic. Biol. Med. 27:1182-1192.
76. Aghdassi E, Allard JP. 2000. Breath alkanes as a marker of oxidative stress in different clinical conditions. Free Radic. Biol. Med. 28:880-886.
77. Quinn MT, Ammons MCB, Deleo FR. 2006. The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction. Clin. Sci. 111:1-20.
78. Banday KM, Pasikanti KK, Chan ECY, Singla R, Rao KV, Chauhan VS, Nanda RK. 2011. Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects. Anal. Chem. 83: 5526-5534.
79. Purkhart R, Köhler H, Liebler-Tenorio E, Meyer M, Becher G, Kikowatz A, Reinhold P. 2011. Chronic intestinal Mycobacterium infection: discrimination viaVOCanalysis in exhaled breath and headspace of feces using differential ion mobility. J. Breath Res. 5:027103. doi:10.1088/1752 -7155/5/2/027103.
80. Peled N, Ionescu R, Nol P, Barash O, McCollum M, VerCauteren K, Koslow M, Stahl R, Rhyan J, Haick H. 2012. Detection of volatile organic compounds in cattle naturally infected with Mycobacterium bovis. Sens. Actuators B Chem. 171-172:588-594.
81. Knobloch H, Koehler H, Commander N, Reinhold P, Turner C, Chambers M. 2009. Volatile organic compound (VOC) analysis for disease detection: proof of principle for field studies detecting paratuberculosis and brucellosis, p 195-197. In Pardo M, Sberveglieri G (ed), CP1137, Olfaction and Electronic Nose: Proceedings of the 13th International Symposium. American Institute of Physics, College Park, MD.
82. Fend R, Goddes R, Lesellier S, Vordermeier HM, Corner LAL, Gormley E, Costello E, Hewinson RG, Marlin DJ, Woodman AC, Chambers MA. 2005. Use of an electronic nose to diagnose Mycobacterium bovis infection in badgers and cattle. J. Clin. Microbiol. 43:1745-1751.
83. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas infection: lessons from a versatile opportunist. Microbes Infect. 2:1051-1060.
84. Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
85. Castric PA. 1983. The influence of oxygen on the Pseudomonas aeruginosa hydrogen cyanide synthase. Curr. Microbiol. 29:19-23.
86. Carterson AJ, Morici LA, Jackson DW, Frisk A, Lizewski SE, Jupiter R, Simpson K, Kunz DA, Davis SH, Schurr JR, Hassett DJ, Schurr MJ. 2004. The transcriptional regulator AlgR controls cyanide production in Pseudomonas aeruginosa. J. Bacteriol. 186:6837-6844.
87. Carroll W, Lenney W, Wang T, Spanel P, Alcock A, Smith D. 2005. Detection of volatile compounds by Pseudomonas aeruginosa using selected ion flow tube mass spectrometry. Pediatr. Pulmonol. 39:452-456.
88. Enderby B, Smith D, Carroll W, Lenney W. 2009. Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis. Pediatr. Pulmonol. 44:142-147.
89. Wang T, Pysanenko A, Dryahina K, Spanel P, Smith D. 2008. Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. J. Breath Res. 2:037013. doi:10.1088/1752-7155/2/3/037013.
90. Stamyr K, Vaittinen O, Jaakola J, Guss J, Metsala M, Johanson G, Halonen L. 2009. Background levels of hydrogen cyanide in human breath measured by infrared cavity ring down spectroscopy. Biomarkers 14:285-291.
91. Schmidt FM, Metsälä M, Vaittinen O, Halonen L. 2011. Background levels and diurnal variations of hydrogen cyanide in breath and emitted from skin. J. Breath Res. 5:046004. doi:10.1088/1752-7155/5/4/046004.
92. Lechner M, Tilg H, Rieder J. 2006. Analysis of volatile compounds emitted by the Helicobacter pylori reference strain NCTC 11637 in vitro. Helicobacter 11:66. doi:10.1111/j.0083-8703.2006.00372.x.
93. Lechner M, Karlseder A, Niederseer D, Lirk P, Neher A, Rieder J. 2005. H. pylori infection increases levels of exhaled nitrate. Helicobacter 10: 385-390.
94. Shestivska V, Nemec A, Drevinek P, Sovova K, Dryahina K, Spanel P. 2011. Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry. Rapid Commun. Mass Spectrom. 25:2459-2467.
95. Mann S. 1966. Über den Geruchsstoff von Pseudomonas aeruginosa. Arch. Mikrobiol. 54:184-190.
96. Habs H, Mann S. 1967. Die Bildung von Ortho-aminoacetophenone durch apyocyaninogene Stämme von Pseudomonas aeruginosa. Zentralbl. Baketriol. Orig. 203:473-477.
97. Cox CD, Parker J. 1979. Use of 2-aminoacetophenone production in identification of Pseudomonas aeruginosa. J. Clin. Microbiol. 9:479-484.
98. Labows JN, McGinley KJ, Webster GF, Leyden JH. 1980. Headspace analysis of volatile metabolites of Pseudomonas aeruginosa and related species by gas chromatography-mass spectrometry. J. Clin. Microbiol. 12:521-526.
99. Scott-Thomas A, Syhre M, Pattemore PK, Epton MJ, Laing R, Pearson JP, Chambers ST. 2010. 2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung. BMC Pulm. Med. 10:56. doi:10.1186/1471-2466-10-56.
100. Scott-Thomas A, Pearson J, Chambers S. 2011. Potential sources of 2-aminoacetophenone to confound the Pseudomonas aeruginosa breath test, including analysis of a food challenge study. J. Breath Res. 5:046002. doi:10.1088/1752-71555/5/4/046002.
101. Rabis T, Sommerwerck U, Anhenn O, Darwiche K, Freitag L, Teschler H, Bödeker B, Madulla S, Baumbach JI. 2011. Detection of infectious agents in the airways by ion mobility spectrometry of exhaled breath. Int. J. Ion Mobil. Spectrom. 14:187-195.
102. Savelev SU, Perry JD, Bourke SJ, Jary H, Taylor R, Fisher AJ, Corris PA, Petrie M, De Soyza A. 2011. Volatile biomarkers of Pseudomonas aeruginosa in cystic fibrosis and noncystic fibrosis bronchiectasis. Lett. Appl. Microbiol. 52:610-613.
103. Lin SJ, Scharanz J, Teutsch SM. 2001. Aspergillosis case fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
104. Syhre M, Scotter JM, Chambers ST. 2008. Investigation into the production of 2-pentylfuran by Aspergillus fumigatus and other diagnostics: progress toward a breath test for invasive Aspergillus fumigatus. Med. Mycol. 46:209-215.
105. Chambers S, Syhre M, Murdoch D, McCartin F, Epton MJ. 2009. Detection of 2-pentylfuran in the breath of patients with Aspergillus fumigatus. Med. Mycol. 47:468-476.
106. Chambers ST, Bhandari S, Scott-Thomas A, Syhre M. 2011. Novel diagnostics: progress toward a breath test for invasive Aspergillus fumigatus. Med. Microbiol. 49(Suppl 1):S54-S61. doi:10.3109/13693786.2010.508187.
107. Bhandari S, Chambers S, Pearson J, Syhre M, Epton M, Scott-Thomas A. 2011. Determining the limits and confounders for the 2-pentylfuran breath test by gas chromatography/mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879:2815-2820.
108. Probert CSJ, Jones PRH, Ratcliffe NM. 2004. A novel method for rapidly diagnosing the causes of diarrhea. Gut 53:58-61.
109. Garner CE, Smith S, Bardhan PK, Ratcliffe NM, Probert CS. 2009. A pilot study of faecal volatile organic compounds in faeces from cholera patients in Bangladesh to determine their utility in disease diagnosis. Trans. R. Soc. Trop. Med. Hyg. 103:1171-1173.
110. Pakodi F, Abdel-Salam OME, Debreceni A, Mozsik G. 2000. Helicobacter pylori. One bacterium and a broad spectrum of human disease. J. Physiol. Paris 94:139-152.
111. Gisbert JP, Pajares JM. 2004. 13C-urea breath test in the diagnosis of Helicobacter pylori infection-a critical review. Aliment. Pharmacol. Ther. 20:1001-1017.
112. Ulanowska A, Kowalowski T, Hrynkiewicz K, Jackowski M, Buszewski B. 2011. Determination of volatile organic compounds in human breath for Helicobacter pylori detection by SPME-GC/MS. Biomed. Chromatogr. 25:391-397.
113. Pauling L, Robinson AB, Teranishi R, Cary P. 1971. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. U. S. A. 68:2374-2376.
114. Hayward NJ, Jeavons TH. 1977. Assessment of technique for rapid detection of Escherichia coli and Proteus species in urine by head-space gas-liquid chromatography. J. Clin. Microbiol. 6:202-208.
115. Coloe PJ. 1978. Headspace gas-liquid chromatography for rapid detection of Escherichia coli and Proteus mirabilis in urine. J. Clin. Pathol. 31:361-364.
116. Hayward NJ. 1983. Headspace gas-liquid chromatography for the rapid laboratory diagnosis of urinary tract infections caused by enterobacteria. J. Chromatogr. 274:27-35.
117. Davies T, Hayward NJ. 1984. Volatile products from acetylcholine as markers in the rapid urine test using headspace gas-liquid chromatography. J. Chromatogr. 307:11-21.
118. Pavlou A, Magan N, McNulty C, Jones J, Sharp D, Brown J, Turner AP. 2002. Use of an electronic nose system for diagnosis of urinary tract infections in vivo. Biosens. Bioelectron. 17:893-899.
119. Aathithan S, Plant JC, Chaudry AN, French GL. 2001. Diagnosis of bacteriuria by detection of volatile organic compounds in urine using an automated headspace analyzer with multiple conducting polymer sensors. J. Clin. Microbiol. 39:2590-2593.
120. Bean H, Dimandja D, Jean-Marie D, Hill JE. 2012. Bacterial volatile discovery using solid phase microextraction and comprehensive twodimensional gas chromatography-time-of-flight mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 901:41-46.
121. Preti G, Thaler E, Hanson CW, Troy M, Eades J, Gelperin A. 2009. Volatile compounds characteristic of sinus-related bacteria and infected sinus mucus: analysis by solid-phase microextraction and gas chroma- tography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:2011-2018.
122. Mohamed E, Bruno E, Linder R, Alessandrini M, Di Girolamo A, Poppl SJ, De Lorenzo A. 2003. A novel method for diagnosing chronic rhinosinusitis based on an electronic nose. An. Otorhinolaringol. Ibero Am. 30:447-457.
123. Bruno E, Alessandrini M, Ottaviani F, Delfini A, Di Pierro D, Camillo A, De Lorenzo A. 2008. Can the electronic nose diagnose chronic rhinosinusitis? A new experimental study. Eur. Arch. Otorhinolaryngol. 265:425-428.
124. Hockstein NG, Thaler ER, Torigian D, Miller WT, Deffenderfer O, Hanson CW. 2004. Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope 114:1701-1705.
125. Hanson CW, Thaler ER. 2005. Electronic nose prediction of a clinical pneumonia score: biosensors and microbes. Anesthesiology 102:63-68.
126. Hockstein NG, Thaler ER, Lin Y, Lee DD, Hanson CW. 2005. Correlation of pneumonia score with electronic nose signature: a prospective study. Ann. Otol. Rhinol. Laryngol. 114:504-508.
127. Parry AD, Chadwick PR, Simon D, Oppenheim B, McCollum CN. 1995. Leg ulcer odour detection identifies beta-haemolytic streptococcal infection. J. Wound Care 4:404-406.
128. Byun H, Persaud KC, Pisanelli AM. 2010. Wound-state monitoring for burn patients using E-nose/SPME system. ETRI J. 32(3):440-446.
129. Greenwood JE, Crawley BA, Clark SL, Chadwick PR, Ellison DA, Oppenheim BA, McCollum CN. 1997. Monitoring wound healing by odor. J. Wound Care 6:219-221.
130. Thomas AN, Riazanskaia S, Cheung W, Xu Y, Goodacre R, Thomas CLP, Baguneid MS, Bayat A. 2010. Novel noninvasive identification of biomarkers by analytical profiling of chronic wounds using volatile organic compounds. Wound Repair Regen. 18:391-400.
131. Chandiok S, Crawley BA, Oppenheim BA, Chadwick P, Higgins S, Persaud KC. 1997. Screening for bacterial vaginosis: a novel application of artificial nose technology. J. Clin. Pathol. 50:790-791.
132. Hay P, Tummon A, Ogunfile M, Adebiyi A, Adefowora A. 2003. Evaluation of a novel diagnostic test for bacterial vaginosis: the electronic nose. Int. J. STD AIDS 14:114-118.
133. Ruzsanyi V, Baumbach JI, Sielemann S, Litterst P, Westhoff M, Freitag L. 2005. Detection of human metabolites using multicapillary columns coupled to ion mobility spectrometers. J. Chromatogr. A 1084: 145-151.
134. American Thoracic Society, European Respiratory Society. 2005. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric acid and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 171:912-930.
135. Khalid TY, Saad S, Greenman J, de Lacy Costello B, Probert CSJ, Ratcliffe NM. 2013. Volatiles from anaerobes confounding breath biomarker discovery. J. Breath Res. 7:017114. doi:10.1088/1752-7155/7/1 /017114.